CytoDyn Inc. (the "Company") (OTC:CYDY) announced that it is providing additional funding to extend the current study being conducted by Dr. Eric S. Rosenberg at Massachusetts General Hospital. Details can be found at www.clinicaltrials.gov by entering "Cytolin." The Company's decision to extend the study was based on discussions with Dr. Rosenberg and a review of the existing data.
"We are pleased that Dr. Rosenberg has completed his initial analysis regarding the potential mechanisms of action of Cytolin, and given the data set to date, a decision was made by the Company and Dr. Rosenberg to extend the study," said Kenneth J. Van Ness, President and CEO of the Company. The extension will allow Dr. Rosenberg to further explore the initial findings regarding the potential mechanism of action. "We look forward to continuing our studies with the Company assessing the mechanism of action of Cytolin," said Dr. Rosenberg.